Stock Financial Ratios, Dividends, Split History

STX / Seagate Technology PLC financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)16,554.99
Enterprise Value ($M)18,023.64
Book Value ($M)1,061.00
Book Value / Share3.73
Price / Book16.05
NCAV ($M)-2,779.00
NCAV / Share-9.76
Price / NCAV-6.99
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 296,000,000
Common Stock Shares Outstanding 291,799,561
Weighted Average Number Of Diluted Shares Outstanding 299,000,000
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 291,813,271
Scoring Models
Piotroski F-Score7.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.12
Return on Assets (ROA)0.09
Return on Equity (ROE)0.48
Balance Sheet (mrq) ($M)
Quick Ratio1.25
Current Ratio1.58
Income Statement (mra) ($M)
Sales Revenue Net10,771,000,000.00
Operating Income1,054.00
Net Income772.00
Earnings Per Share Diluted2.58
Earnings Per Share Basic2.61
Cash Flow Statement (mra) ($M)
Cash From Operations1,916.00
Cash from Investing-459.00
Cash from Financing-459.00
Identifiers and Descriptors
Central Index Key (CIK)1137789
Related CUSIPS
G7945M957 0G794M107 B58JVZ5US B58JVZ500 0G7945M10 052580676 G7945M909 SB58JVZ57 G7945M907 G7945J104 G7945M958

Split History

Stock splits are used by Seagate Technology PLC to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

No 'calm and easy' summer, look for buying opportunities: Larry Glazer

2018-06-15 cnbc
Investors need to be vigilant as trade war talk heats up, but there may be some buying opportunities to be had amid the volatility, veteran fund manager Larry Glazer told CNBC on Friday. (13-0)

The Zacks Analyst Blog Highlights: Seagate Technology, Micron Technology, Delta Apparel, Malibu Boats and Rocky Brands

2018-06-13 zacks
Chicago, IL – June 13, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Seagate Technology Plc (STX - Free Report) , Micron Technology, Inc. (MU - Free Report) , Delta Apparel, Inc. (DLA - Free Report) , Malibu Boats, Inc. (166-1)

Are Tech Bubble Fears Overblown? 6 Top-Ranked Picks

2018-06-13 zacks
Tech stocks have been on a tear this year and Wednesday’s session was no exception with the Nasdaq closing 0.5% higher. Overall, tech stocks have been largely responsible for the long-running market rally. But bubble fears are making a comeback courtesy of a bunch of leading analysts and market watchers. (499-0)

The Top 20 Stocks of 2018

2018-06-12 investorplace
As we end the first half of 2018, here are a few questions every investor should be asking: (1087-5)

Trump, Kim Clinch Historic Deal: 6 Top-Ranked Winners

2018-06-12 zacks
Exceptional bonhomie was on display when President Trump and North Korea’s leader Kim Jong Un met in Singapore on Tuesday. This was the first meeting between a sitting U.S. President and a North Korean chairman. (135-0)

CUSIP: G7945M107